Clinical Trial Update: Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer [EARLY_Phase 1]

View source ↗

Summary

Phase 1 trial evaluating durvalumab given before surgery in patients with oral cavity and/or oropharyngeal squamous cell carcinoma; the study was terminated and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2025-03-17